Smith & Nephew Plc Katarzyna Mazur-Hofsaess joins Smith+Nephew as NED (6351C)
20 Octubre 2020 - 04:00AM
UK Regulatory
TIDMSN.
RNS Number : 6351C
Smith & Nephew Plc
20 October 2020
Katarzyna Mazur-Hofsaess joins Smith+Nephew's Board as
Non-Executive Director
20 October 2020
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology
business, is pleased to announce the appointment of Katarzyna
Mazur-Hofsaess as a Non-Executive Director.
Katarzyna has a strong track record in senior leadership within
the MedTech industry and is a qualified medical doctor.
Since 2017 Katarzyna has served as Chief Executive Officer for
the EUR2.7 billion EMEA business of Fresenius Medical Care AG &
Co. KGaA, the German-listed renal care company. Previously she
spent eight years at Zimmer Biomet (previously Zimmer) as
President, EMEA, and held leadership roles at Abbott Laboratories,
Allergy Therapeutics and Roche.
Katarzyna qualified as a doctor from the Medical University of
Gdańsk, Poland in 1987 and completed an Executive MBA at the
University of Minnesota, US, in 2002. Katarzyna is a Polish and
German national.
Roberto Quarta, Chair of Smith+Nephew, said:
"We are delighted to have secured Katarzyna as a Non-Executive
Director. Her deep industry knowledge, senior leadership experience
and medical background make her an excellent addition to the Board
team."
Katarzyna will join the Board on 1 November 2020.
-ENDS-
Enquiries
Investors
Andrew Swift +44 (0) 1923 477433
Smith+Nephew
Media
Charles Reynolds +44 (0) 1923 477314
Smith+Nephew
Susan Gilchrist / Ayesha Bharmal +44 (0) 20 7404 5959
Brunswick
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that
exists to restore people's bodies and their self-belief by using
technology to take the limits off living. We call this purpose
'Life Unlimited'. Our 17,500+ employees deliver this mission every
day, making a difference to patients' lives through the excellence
of our product portfolio, and the invention and application of new
technologies across our three global franchises of Orthopaedics,
Advanced Wound Management and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.1 billion in 2019.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms 'Group' and 'Smith+Nephew' are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please visit
www.smith-nephew.com and follow us on Twitter , LinkedIn ,
Instagram or Facebook .
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: risks
related to the impact of COVID-19, such as the depth and longevity
of its impact, government actions and other restrictive measures
taken in response, material delays and cancellations of elective
procedures, reduced procedure capacity at medical facilities,
restricted access for sales representatives to medical facilities,
or our ability to execute business continuity plans as a result of
COVID-19; economic and financial conditions in the markets we
serve, especially those affecting health care providers, payers and
customers (including, without limitation, as a result of COVID-19);
price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers
(including, without limitation, as a result of COVID-19);
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that
Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith+Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith+Nephew are
qualified by this caution. Smith+Nephew does not undertake any
obligation to update or revise any forward-looking statement to
reflect any change in circumstances or in Smith+Nephew's
expectations.
Trademark of Smith+Nephew. Certain marks registered US Patent
and Trademark Office.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAPPGRWUUPUURU
(END) Dow Jones Newswires
October 20, 2020 05:00 ET (09:00 GMT)
Smith & Nephew (LSE:SN.)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Smith & Nephew (LSE:SN.)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024